← Eichor
Study identifier: NCT07272902 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication

Condition: Atrial Fibrillation (AF) · Heart Failure With Mildly Reduced Ejection Fraction · Heart Failure With Preserved Ejection Fraction (HFPEF)  ·  Sponsor: Nova Scotia Health Authority

PhaseNA
Planned participants84
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function. Patients will randomly be assigned to either rhythm control using catheter ablation or rate control using medicines. The pilot phase will determine if a larger study can be successfully carried out to see which approach better improves survival, reduces hospitalizations, and enhances quality of life.

This description comes directly from the study's public registry record.

Talk to the study team

Laura Hamilton, BSC, MAHSR  ·  902-473-7226  ·  laura.hamilton@nshealth.ca

Katie Kawulka, BScN, RN  ·  902-473-7684  ·  katie.kawulka@nshealth.ca

Always discuss trial participation with your own doctor first.

Locations (1)

QEII HSCHalifax, Nova Scotia, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07272902